BR112014000810A8 - Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos - Google Patents
Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídosInfo
- Publication number
- BR112014000810A8 BR112014000810A8 BR112014000810A BR112014000810A BR112014000810A8 BR 112014000810 A8 BR112014000810 A8 BR 112014000810A8 BR 112014000810 A BR112014000810 A BR 112014000810A BR 112014000810 A BR112014000810 A BR 112014000810A BR 112014000810 A8 BR112014000810 A8 BR 112014000810A8
- Authority
- BR
- Brazil
- Prior art keywords
- hypertension
- inflammation
- gamma
- treatment
- methods
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000010408 sweeping Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506848P | 2011-07-12 | 2011-07-12 | |
| PCT/US2012/046549 WO2013010034A2 (en) | 2011-07-12 | 2012-07-12 | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014000810A2 BR112014000810A2 (pt) | 2017-06-13 |
| BR112014000810A8 true BR112014000810A8 (pt) | 2022-11-29 |
Family
ID=47506934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014000810A BR112014000810A8 (pt) | 2011-07-12 | 2012-07-12 | Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10975033B2 (enExample) |
| EP (1) | EP2731597B1 (enExample) |
| JP (1) | JP6280033B2 (enExample) |
| KR (2) | KR20140050661A (enExample) |
| CN (2) | CN103796648B (enExample) |
| AU (1) | AU2012281061B2 (enExample) |
| BR (1) | BR112014000810A8 (enExample) |
| CA (1) | CA2844150C (enExample) |
| ES (1) | ES2970814T3 (enExample) |
| HU (1) | HUE065757T2 (enExample) |
| MX (1) | MX383365B (enExample) |
| PL (1) | PL2731597T3 (enExample) |
| WO (1) | WO2013010034A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130018478A (ko) * | 2011-08-09 | 2013-02-25 | 주식회사 엘지화학 | 신규한 구조의 이차전지 팩 |
| US10166248B1 (en) * | 2015-12-21 | 2019-01-01 | Vanderbilt University | Methods of preventing platelet activation |
| US11400103B2 (en) * | 2015-12-21 | 2022-08-02 | Vanderbilt University | Methods of preventing platelet activation |
| CA3030036A1 (en) * | 2016-07-06 | 2018-01-11 | Vanderbilt University | Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan |
| PL3481505T3 (pl) * | 2016-07-07 | 2026-01-26 | Vanderbilt University | Zapobieganie i leczenie migotania/trzepotania przedsionków za pomocą środków wychwytujących gamma-ketoaldehyd |
| EP3510014B8 (en) * | 2016-09-06 | 2026-07-29 | MTI Biotech, Inc. | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| EP4385576A3 (en) * | 2016-11-15 | 2024-09-04 | Vanderbilt University | Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension |
| HUE066390T2 (hu) | 2017-04-27 | 2024-07-28 | Univ Vanderbilt | Eljárások ateroszklerózis kezelésére gamma-ketoaldehid-szkevendzserekkel |
| US20210023032A1 (en) | 2017-09-05 | 2021-01-28 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
| WO2019050967A1 (en) * | 2017-09-05 | 2019-03-14 | Metabolic Technologies, Inc. | COMPOSITIONS AND METHODS OF USING GAMMA-KETOALDEHYDE SENSORS TO TREAT, PREVENT, OR IMPROVE LIVER FIBROSIS |
| CN109836341B (zh) * | 2017-11-28 | 2021-08-27 | 江阴技源药业有限公司 | 一种水杨胺醋酸盐的制备方法 |
| US20200197323A1 (en) * | 2018-12-21 | 2020-06-25 | Vanderbilt University | Methods for suppressing accumulation of reflux-induced protein adducts |
| US20230069820A9 (en) * | 2019-09-24 | 2023-03-02 | Vanderbilt University | Use of 2-hydroxybenzylamine for the treatment of systemic lupus |
| WO2021154877A1 (en) * | 2020-01-27 | 2021-08-05 | Vanderbilt University | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof |
| CN118652245B (zh) * | 2024-08-21 | 2024-11-12 | 首都医科大学附属北京儿童医院 | 一种化合物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740439A (en) * | 1968-06-24 | 1973-06-19 | Ciba Geigy Corp | Treating hypertension with beta-aminoalkane carboxylic acids |
| US3794734A (en) | 1971-03-03 | 1974-02-26 | Merck & Co Inc | Methods of treating edema and hypertension using certain 2-aminoethylphenols |
| US4123537A (en) * | 1977-05-26 | 1978-10-31 | Merck & Co., Inc. | 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema |
| US8178516B2 (en) * | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| AU5659796A (en) | 1995-05-19 | 1996-11-29 | Kissei Pharmaceutical Co. Ltd. | 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors |
| US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
| ATE333868T1 (de) | 2000-11-02 | 2006-08-15 | Univ South Carolina | Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas |
| US6824786B2 (en) * | 2001-11-27 | 2004-11-30 | Ruey J. Yu | Compositions comprising phenyl-glycine derivatives |
| US7705054B1 (en) * | 2004-10-20 | 2010-04-27 | Vanderbilt University | Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases |
| EP2207555B1 (en) * | 2007-10-05 | 2013-07-24 | InDex Pharmaceuticals AB | Oligonucleotides for the treatment or alleviation of edema |
| KR100973343B1 (ko) * | 2008-02-01 | 2010-07-30 | 롯데칠성음료주식회사 | 기호성이 우수한 혼합차 조성물 및 그 제조방법 |
| CN101305759B (zh) * | 2008-06-19 | 2011-09-07 | 成都大学 | 一种苦荞保健茶及其制备方法 |
| CN101843671A (zh) * | 2009-03-25 | 2010-09-29 | 王文祥 | 苦荞托毒丸及其制备方法 |
| EP2477594A4 (en) * | 2009-07-15 | 2013-03-13 | Univ Vanderbilt | ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY |
| CN101606986A (zh) * | 2009-07-29 | 2009-12-23 | 李钢 | 一种具有降糖作用的组合物及其药物 |
-
2012
- 2012-07-12 US US14/232,615 patent/US10975033B2/en active Active
- 2012-07-12 CA CA2844150A patent/CA2844150C/en active Active
- 2012-07-12 BR BR112014000810A patent/BR112014000810A8/pt not_active Application Discontinuation
- 2012-07-12 JP JP2014520341A patent/JP6280033B2/ja active Active
- 2012-07-12 WO PCT/US2012/046549 patent/WO2013010034A2/en not_active Ceased
- 2012-07-12 ES ES12811030T patent/ES2970814T3/es active Active
- 2012-07-12 CN CN201280044440.6A patent/CN103796648B/zh active Active
- 2012-07-12 MX MX2014000515A patent/MX383365B/es unknown
- 2012-07-12 AU AU2012281061A patent/AU2012281061B2/en active Active
- 2012-07-12 EP EP12811030.1A patent/EP2731597B1/en active Active
- 2012-07-12 HU HUE12811030A patent/HUE065757T2/hu unknown
- 2012-07-12 KR KR1020147003650A patent/KR20140050661A/ko not_active Ceased
- 2012-07-12 PL PL12811030.1T patent/PL2731597T3/pl unknown
- 2012-07-12 KR KR1020197016572A patent/KR102050700B1/ko active Active
- 2012-07-12 CN CN201910951171.5A patent/CN111494352A/zh active Pending
-
2021
- 2021-04-13 US US17/229,593 patent/US20210261508A1/en not_active Abandoned
-
2024
- 2024-10-16 US US18/917,759 patent/US20250034093A1/en active Pending
- 2024-10-16 US US18/917,789 patent/US20250214939A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2844150C (en) | 2019-09-03 |
| BR112014000810A2 (pt) | 2017-06-13 |
| JP2014524918A (ja) | 2014-09-25 |
| MX383365B (es) | 2025-03-13 |
| EP2731597A2 (en) | 2014-05-21 |
| US10975033B2 (en) | 2021-04-13 |
| AU2012281061A1 (en) | 2014-02-20 |
| PL2731597T3 (pl) | 2024-04-29 |
| MX2014000515A (es) | 2014-03-27 |
| US20250034093A1 (en) | 2025-01-30 |
| ES2970814T3 (es) | 2024-05-30 |
| US20140256774A1 (en) | 2014-09-11 |
| KR20140050661A (ko) | 2014-04-29 |
| AU2012281061B2 (en) | 2017-08-03 |
| CN103796648B (zh) | 2019-10-25 |
| KR102050700B1 (ko) | 2019-11-29 |
| CN103796648A (zh) | 2014-05-14 |
| WO2013010034A3 (en) | 2013-03-28 |
| HUE065757T2 (hu) | 2024-06-28 |
| WO2013010034A2 (en) | 2013-01-17 |
| EP2731597B1 (en) | 2023-12-20 |
| CA2844150A1 (en) | 2013-01-17 |
| KR20190069607A (ko) | 2019-06-19 |
| JP6280033B2 (ja) | 2018-02-14 |
| CN111494352A (zh) | 2020-08-07 |
| EP2731597C0 (en) | 2023-12-20 |
| US20250214939A1 (en) | 2025-07-03 |
| EP2731597A4 (en) | 2015-04-08 |
| US20210261508A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383365B (es) | Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos. | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| EA201890411A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| EA201291031A1 (ru) | Способ лечения ожирения с применением антиоксидантных модуляторов воспаления | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
| BRPI0908276B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| EA201491221A1 (ru) | Новые молекулы, ингибирующие jnk, для лечения различных болезней | |
| IN2015DN00450A (enExample) | ||
| EA201690745A1 (ru) | Способы лечения и предотвращения болезни "трансплантат против хозяина" | |
| EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| EA201591843A1 (ru) | Способы лечения несовершенного остеогенеза | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| MX2020003035A (es) | Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |